Targeting deubiquitinases in CLL.
Open accessAbstract
patients with advanced SM have reason for optimism: the findings of Jawhar and colleagues provide a molecular footing to help navigate the steep mountain toward cure.Conflict-of-interest disclosure: J.G. served as Chairman of the Study Steering Committee for the Novartis-sponsored global trial of midostaurin in advanced SM.He has received funding to conduct trials of midostaurin and BLU
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
USP7 inhibition with HBX19,818 sensitizes chronic lymphoblastic leukemia cells to cyclophosphamide and mitomycin C in cells with defects in p53 or ATM kinase.
“USP7 inhibition with the compound HBX19, 818, for example, was shown to sensitize chronic lymphoblastic leukemia cells to the chemotherapeutic agents cyclophosphamide and mitomycin C in cells with defects in p53 or the ATM kinase (Agathanggelou et al., 2017; Sampath, 2017).”
From USP7 Is a Master Regulator of Genome Stability (2020) · cites this paper as Sampath, 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The DNA Damage Response: Making It Safe to Play with Knives
Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368 · see citing works
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400029 · Cited by 1,275 · see citing works
DNA repair mechanisms in dividing and non-dividing cells
Iyama, T., & Wilson, D. M. (2013) · DNA Repair · doi:10.1016/j.dnarep.2013.04.015 · Cited by 697 · see citing works
Maddocks, K. J., Ruppert, A. S., Lozanski, G., Heerema, N. A., Zhao, W., Abruzzo, L., Lozanski, A., Davis, M., Gordon, A., Smith, L. L., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2014.218 · Cited by 584 · see citing works
Nadeu, F., Delgado, J., Royo, C., Baumann, T., Stanković, T., Pinyol, M., Jares, P., Navarro, A., Martin‐García, D., Beà, S., et al. (2016) · Blood · doi:10.1182/blood-2015-07-659144 · Cited by 337 · see citing works
Functions of PARylation in DNA Damage Repair Pathways
Wei, H., & Yu, X. (2016) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.05.001 · Cited by 296 · see citing works
Recurrent mutations refine prognosis in chronic lymphocytic leukemia
Baliakas, P., Hadzidimitriou, A., Sutton, L.-A., Rossi, D., Minga, E., Villamor, N., Larráyoz, M., Kmínková, J., Agathangelidis, A., Davis, Z. A., et al. (2014) · Leukemia · doi:10.1038/leu.2014.196 · Cited by 287 · see citing works
The Multifaceted Roles of USP7: New Therapeutic Opportunities
Nicholson, B., & Kumar, S. (2011) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-011-9185-5 · Cited by 243 · see citing works
An in vivo analysis of MMC-induced DNA damage and its repair
Lee, Y.-J., Park, S.-J., Ciccone, S. L. M., Kim, C.-R., & Lee, S. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi254 · Cited by 77 · see citing works
Agathanggelou, A., Smith, E., Davies, N. J., Kwok, M., Zlatanou, A., Oldreive, C. E., Mao, J., Da Costa, D., Yadollahi, S., Perry, T., et al. (2017) · Blood · doi:10.1182/blood-2016-12-758219 · Cited by 75 · see citing works
Flagged first, then by citations
Research works printed but not linked: 10
- Jawhar M, Schwaab J, Naumann N, et al. Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. Blood. 2017;130(2):137-145.
- Growney JD, Clark JJ, Adelsperger J, et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood. 2005;106(2):721-724.
- Arock M, Sotlar K, Akin C, et al. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia. 2015;29(6):1223-1232.
- Schwaab J, Schnittger S, Sotlar K, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 2013;122(14):2460-2466.
- Jawhar M, Schwaab J, Schnittger S, et al. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(1) advanced systemic mastocytosis. Leukemia. 2016;30(1):136-143.
- Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861-1869.
- Pardanani A, Lasho T, Elala Y, et al. Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival. Am J Hematol. 2016;91(9):888-893.
- Mascarenhas J. Looking forward: novel therapeutic approaches in chronic and advanced phases of myelofibrosis. Hematol Am Soc Hematol Educ Prog. 2015; 2015:329-339.
- Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374(26):2530-2541.
- Patel KP, Newberry KJ, Luthra R, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015;126(6):790-797.
Cited by
Sorted by citations
USP7 Is a Master Regulator of Genome Stability
Valles, G. J., Bezsonova, I., Woodgate, R., & Ashton, N. W. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00717 · Cited by 114 · see citing works
“USP7 inhibition with the compound HBX19, 818, for example, was shown to sensitize chronic lymphoblastic leukemia cells to the chemotherapeutic agents cyclophosphamide and mitomycin C in cells with defects in p53 or the ATM kinase (Agathanggelou et al., 2017; Sampath, 2017).”
BackgroundSaha, G., Sarkar, S., Mohanta, P. S., Kumar, K., Chakrabarti, S., Basu, M., & Ghosh, M. K. (2022) · Oncogene · doi:10.1038/s41388-022-02486-5 · Cited by 41 · see citing works
Deubiquitinases in hematological malignancies
Lei, H., Wang, J., Hu, J., Zhu, Q., & Wu, Y. (2021) · Biomarker Research · doi:10.1186/s40364-021-00320-w · Cited by 35 · see citing works
Monoclonal Antibodies and Multiple Myeloma: All in All It's Just Another Brick in the Wall?
Musto, P. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0097 · Cited by 5 · see citing works
Asparaginase activity monitoring experience from the Maritimes, Canada
Pike, M., Kulkarni, K. P., & MacDonald, T. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1571196 · Cited by 4 · see citing works
Deubiquitinase as Potential Targets for Cancer Immunotherapy
(2019) · Journal of Cellular Immunology · doi:10.33696/immunology.1.001 · Cited by 1 · see citing works
- Authors
- Sampath, D.
- Affiliations
- The Ohio State University (US)
- Corresponding author
- Sampath, Deepa
- ORCID
- Sampath, Deepa
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2017-07-13
- Volume
- 130
- Issue
- 2
- Pages
- 100-101
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2735729277
- Cited by
- 6
- References
- 10
- Citations by year
- 2022: 1 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 1
- FWCI
- 0.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- deubiquitinase, chronic lymphocytic leukemia, targeted therapy, midostaurin, smoldering multiple myeloma, BTK inhibitors
- MeSH terms
- Deubiquitinating Enzymes, Humans, Leukemia, Lymphocytic, Chronic, B-Cell
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
